Rate this post


cannabis chemical may have a “major impact” in the treatment of pancreatic cancer, according to a new study.
Pancreatic cancer has a five-year survival rate of just nine per cent, according to the American Cancer Society (ACS), and is expected to be the second leading cause of cancer deaths in the United States by 2020.

However, a Harvard University study conducted by researchers at the university’s Dana-Farber Cancer Institute and published in the Frontiers of Oncology has found that FBL-03G – a “non-cannabinoid, non-psychoactive derivative of cannabis” – has “significant therapy potential” in treating the disease.

FBL-03G is a derivative of a cannabis “flavonoid”, naturally occurring compounds found in plants, fruits and vegetables, which are known to have certain health benefits. But this study has found that the flavonoid derivative in question may be able to treat both localised and advanced pancreatic cancer.

“The most significant conclusion is that tumour-targeted delivery of flavonoids, derived from cannabis, enabled both local and metastatic tumour cell kill, significantly increasing survival from pancreatic cancer,” one of the study’s researchers, Dr Wilfred Ngwa, told Yahoo. “This has major significance, given that pancreatic cancer is particularly refractory to current therapies.”

Leave a Reply

Your email address will not be published.